A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2017
At a glance
- Drugs Curcumin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Signpath Pharma
- 06 May 2017 Planned End Date changed from 1 Mar 2017 to 30 Jun 2017.
- 06 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
- 15 Oct 2016 Planned number of patients changed from 28 to 33.